Moving Beyond "Blind Obedience" — When Clinical Observation Demands Evidence-Based Change I. The Clinical Challenge In 1982, frontline treatment for Schistosomiasis (Bilharziasis) in rural Egypt relied on antimonials (IV Tartar Emetic or IM Astiban). While effective at eliminating the parasite, the treatment was associated with a high attrition rate. Many patients abandoned the life-saving therapy midway through the course. II.
The Observation — Understanding the "Why" As a supervisor, investigation revealed two major barriers to patient compliance: Iatrogenic Injury A high prevalence of chemical abscesses at the IV site, likely due to the caustic nature of the undiluted drug. Systemic Toxicity Frequent complaints of cough and chest oppression — well-recognized adverse effects of rapid antimonial administration. III. The Intervention: Challenging the Status Quo Faced with the choice…
